Cellulite News and Research

RSS

Cellulite describes a condition that is claimed to occur in most women, where the skin of the lower limbs, abdomen, and pelvic region becomes dimpled.

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has notified the Company that it is extending the Prescription Drug User Fee Act goal date for the Company's supplemental biologics license application for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease from September 6, 2013 to December 6, 2013.

28 Aug 2013

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome.

26 Mar 2013

Syneron dismisses U.S. patent infringement suit against Eclipse Aesthetics, EndyMed

Syneron Medical Ltd., the leading global aesthetic device company announced today, jointly with EndyMed Medical Ltd. and Eclipse Aesthetics, that Syneron has dismissed its United States patent infringement lawsuit against EndyMed and Eclipse Aesthetics relating to EndyMed's Fractional Skin Resurfacing Products.

22 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Cynosure closes underwritten registered public offering of class A common stock

Cynosure, Inc., a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the closing of its previously announced underwritten registered public offering of class A common stock.

21 Nov 2012

Gateway Aesthetic announces addition of three new procedures

The Gateway Aesthetic Institute & Laser Center in Salt Lake City, Utah is pleased to announce the addition of three new procedures to its broad list of available services in the aesthetics' arena.

5 Nov 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb trial evaluating XIAFLEX for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The Company enrolled 60 patients at eight sites throughout the U.S. and Australia.

30 Jul 2012

Health Canada approves XIAFLEX for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada.

9 Jul 2012

FDA clears Syneron Medical's elos Plus system

Syneron Medical Ltd., the global leader in medical aesthetic products and technology, announced today that it has received United States Food and Drug Administration (FDA) clearance for elos Plus, a next generation multi-platform system featuring the Company's proprietary elos technology.

2 Jul 2012

BioSpecifics commences XIAFLEX Phase II trial in human lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.

27 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Viora offers Reaction Rent-to-Own program to medical aesthetic practitioners in Canada

Viora is excited to announce that its popular "Rent-to-Own" program for Reaction™ will now be offered in Canada to medical aesthetic practitioners. Now Canadian physicians will have the ability to introduce the leading medical aesthetic device for body contouring and skin tightening into their practice at minimal risk - with no capital investment, no financing, and no long term commitment.

2 May 2012

BistroMD, 'The Doctors' team up to help young woman look lose weight

To help celebrate their special Oscars episode, BistroMD, the weight loss program that delivers meals for a lighter, healthier you, is teaming up with The Doctors once again to help one of their featured guests lose weight.

24 Feb 2012

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

23 Feb 2012

Birmingham dermatologist first to offer anti-cellulite Cellulaze procedure

Dr. Barry Ginsburg, a Birmingham, AL based Dermatologist today announced his practice is the first in the state to offer the Cellulaze by Cynosure, the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market.

20 Feb 2012

AACS 2012 announces record attendance at annual scientific meeting

The American Academy of Cosmetic Surgery (AACS) announced its highest attendance in the Academy’s history with more than 700 medical professionals at its 28th Annual Scientific Meeting. The event was held January 18-21, 2012 at Caesars Palace Hotel in Las Vegas.

1 Feb 2012